Plain-English translation of NCT05849467 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging tracer called crefmirlimab (an anti-CD8+ T cell minibody) that can help doctors see where specific immune cells are active in the brains of people with inflammatory neurological diseases. Researchers will inject this tracer into your bloodstream and then use special PET and MRI scans to create pictures showing where these immune cells have gathered in your brain and spinal cord. The goal is to understand how this medication moves through the brain and whether it can help doctors better diagnose and monitor these conditions.
Currently, doctors have limited ways to directly see which immune cells are causing inflammation in the brains of people with these diseases. This medication may help doctors visualize immune activity without invasive procedures, which could lead to better diagnosis, monitoring, and treatment decisions in the future.
You likely qualify if…
You likely don't qualify if…
Depending on which disease group you join, you will have between 4 and 7 study visits over several months. At your first major visit, you will receive an MRI scan of your brain and/or spinal cord, followed by an injection of the imaging tracer medication into your vein. The next day, you will have a PET scan to see where the tracer has traveled in your brain. Some participants will be asked to return for additional scans to track changes over time. The entire study process is designed to be noninvasive — meaning no surgery or biopsies — and the imaging itself is painless.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States